Nothing Special   »   [go: up one dir, main page]

SG11201507360XA - Processes for the preparation of an apoptosis-inducing agent - Google Patents

Processes for the preparation of an apoptosis-inducing agent

Info

Publication number
SG11201507360XA
SG11201507360XA SG11201507360XA SG11201507360XA SG11201507360XA SG 11201507360X A SG11201507360X A SG 11201507360XA SG 11201507360X A SG11201507360X A SG 11201507360XA SG 11201507360X A SG11201507360X A SG 11201507360XA SG 11201507360X A SG11201507360X A SG 11201507360XA
Authority
SG
Singapore
Prior art keywords
apoptosis
processes
preparation
inducing agent
inducing
Prior art date
Application number
SG11201507360XA
Inventor
Jufang Barkalow
Jean-Christophe Califano
Vincent S Chan
Alan C Christensen
Timothy A Grieme
Yi-Yin Ku
Mathew M Mulhern
Yu-Ming M Pu
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of SG11201507360XA publication Critical patent/SG11201507360XA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00Preparation of carboxylic acid esters
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/45Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
    • C07C45/455Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation with carboxylic acids or their derivatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00Compounds having —CHO groups
    • C07C47/38Unsaturated compounds having —CHO groups bound to carbon atoms of rings other than six—membered aromatic rings
    • C07C47/457Unsaturated compounds having —CHO groups bound to carbon atoms of rings other than six—membered aromatic rings containing halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00Preparation of carboxylic acid esters
    • C07C67/30Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/333Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton
    • C07C67/343Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Health & Medical Sciences (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compounds Of Unknown Constitution (AREA)
SG11201507360XA 2013-03-13 2014-03-12 Processes for the preparation of an apoptosis-inducing agent SG11201507360XA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361780621P 2013-03-13 2013-03-13
US201461947850P 2014-03-04 2014-03-04
PCT/US2014/024224 WO2014165044A1 (en) 2013-03-13 2014-03-12 Processes for the preparation of an apoptosis-inducing agent

Publications (1)

Publication Number Publication Date
SG11201507360XA true SG11201507360XA (en) 2015-10-29

Family

ID=50439506

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201701680YA SG10201701680YA (en) 2013-03-13 2014-03-12 Processes for the preparation of an apoptosis-inducing agent
SG11201507360XA SG11201507360XA (en) 2013-03-13 2014-03-12 Processes for the preparation of an apoptosis-inducing agent

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201701680YA SG10201701680YA (en) 2013-03-13 2014-03-12 Processes for the preparation of an apoptosis-inducing agent

Country Status (31)

Country Link
EP (5) EP4019491A1 (en)
JP (2) JP6357220B2 (en)
KR (1) KR102230339B1 (en)
CN (3) CN105164128B (en)
AU (2) AU2014248742B2 (en)
BR (3) BR122021025053B1 (en)
CA (3) CA3090936C (en)
CL (1) CL2015002548A1 (en)
CR (1) CR20150495A (en)
CY (1) CY1120576T1 (en)
DK (1) DK2970263T3 (en)
ES (1) ES2683378T3 (en)
HK (2) HK1216644A1 (en)
HR (1) HRP20181273T1 (en)
HU (1) HUE039046T2 (en)
IL (2) IL240779B (en)
LT (1) LT2970263T (en)
MX (1) MX365343B (en)
MY (1) MY192466A (en)
PE (2) PE20191685A1 (en)
PH (2) PH12015501960A1 (en)
PL (1) PL2970263T3 (en)
PT (1) PT2970263T (en)
RS (1) RS57569B1 (en)
RU (1) RU2660424C2 (en)
SG (2) SG10201701680YA (en)
SI (1) SI2970263T1 (en)
TW (2) TWI735759B (en)
UA (1) UA118667C2 (en)
UY (3) UY39847A (en)
WO (1) WO2014165044A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104370905B (en) * 2014-10-22 2016-06-01 南京友杰医药科技有限公司 The synthesis of Bcl-2 AB combined inhibitor T-199
US11001582B2 (en) 2016-03-10 2021-05-11 Assia Chemical Industries Ltd. Solid state forms of Venetoclax and processes for preparation of Venetoclax
CN107089981A (en) * 2017-04-24 2017-08-25 杭州科耀医药科技有限公司 A kind of inhibitor Venetoclax of BCL 2 synthetic method
EP3672975B1 (en) 2017-08-23 2023-04-12 Guangzhou Lupeng Pharmaceutical Company Ltd. Condensed heterocyclic derivatives as bcl-2 inhibitors for the treatment of neoplastic diseases
CN108037196B (en) * 2017-11-23 2020-06-23 中山奕安泰医药科技有限公司 Detection method of 3-nitro-4- [ [ (tetrahydro-2H-pyran-4-yl) methyl ] amino ] benzenesulfonamide
SG11202005985PA (en) 2018-01-10 2020-07-29 Recurium Ip Holdings Llc Benzamide compounds
WO2020003272A1 (en) 2018-06-29 2020-01-02 Fresenius Kabi Oncology Ltd. An improved process for the preparation of venetoclax
CN108997333A (en) * 2018-07-04 2018-12-14 江苏中邦制药有限公司 A kind of preparation method of -2 inhibitor ABT-199 of the B cell lymphoma factor
WO2020023435A1 (en) 2018-07-24 2020-01-30 Albany Molecular Research, Inc. Venetoclax basic salts and processes for the purification of venetoclax
WO2020041405A1 (en) 2018-08-22 2020-02-27 Newave Pharmaceutical Inc. Bcl-2 inhibitors
WO2020049599A1 (en) * 2018-09-07 2020-03-12 Msn Laboratories Private Limited, R&D Center Process for the preparation of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1- yl]methyl}piperazin-1-yl)-n-({3-nitro-4-[(tetrahydro-2h-pyran-4-ylmethyl)amino] phenyl}sulfonyl)-2-(1h-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide)
CN112079795B (en) * 2020-09-16 2022-12-09 广东莱佛士制药技术有限公司 Synthetic method of Venetork intermediate and analogue thereof
IT202100025976A1 (en) 2021-10-06 2023-04-06 Univ Degli Studi Di Perugia Combination of active substances for the treatment of acute myeloid leukemia (AML) with nucleophosmin (NPM1) mutation
CN114163369A (en) * 2021-12-17 2022-03-11 武汉工程大学 Preparation method of sulfur/oxygen ester group-containing aromatic hydrocarbon compound
CN116496239A (en) * 2022-12-14 2023-07-28 南京哈柏医药科技有限公司 Synthesis method of key intermediate and bulk drug of vitamin Nadotox
EP4421075A1 (en) 2023-02-27 2024-08-28 KRKA, d.d., Novo mesto Process for the preparation of venetoclax and intermediates used therein

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB585940A (en) 1944-09-01 1947-02-28 Kodak Ltd Bicyclic compounds containing the diphenylamine grouping, process of making them and their use in the colouration of textile materials other than cellulose
US3813443A (en) 1970-11-18 1974-05-28 Us Agriculture Boll weevil sex attractant
KR100838617B1 (en) 1999-02-10 2008-06-16 아스트라제네카 아베 Quinazoline derivatives as angiogenesis inhibitors
EP2463268B1 (en) 2004-12-02 2013-08-28 Daiichi Sankyo Company, Limited 4-(Aminomethyl)benzoic acids as intermediates for the preparation of chymase inhibiting 1,4-diazepan-2,5-dione compounds
CN1827582A (en) * 2006-04-18 2006-09-06 江苏中丹化工集团公司 Process for preparing 6-[3-(1-adamantyl)-4-methoxy phenyl]-2-methyl naphthoate
KR20100017508A (en) * 2007-04-30 2010-02-16 아보트 러보러터리즈 Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
MX2010010262A (en) 2008-03-20 2010-12-06 Abbott Lab Methods for making central nervous system agents that are trpv1 antagonists.
UA108193C2 (en) * 2008-12-04 2015-04-10 APOPTOZINDUCE FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTO-IMMUNE DISEASES
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
NZ593593A (en) * 2009-01-19 2013-11-29 Abbvie Inc Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8546399B2 (en) * 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
CN101990094B (en) 2009-08-05 2012-11-21 炬力集成电路设计有限公司 Code stream analysis method and device
CN102030651A (en) * 2009-09-28 2011-04-27 莱阳市盛华科技有限公司 Synthesis method of 2-fluo-4-bromobiphenyl ethyl formate
TWI520960B (en) * 2010-05-26 2016-02-11 艾伯維有限公司 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
DE102010027213A1 (en) * 2010-07-15 2012-01-19 Continental Automotive Gmbh Method and control device for controlling an internal combustion engine
WO2012058392A1 (en) 2010-10-29 2012-05-03 Abbott Laboratories Solid dispersions containing an apoptosis-inducing agent
UA113500C2 (en) 2010-10-29 2017-02-10 MEL EXTRUSION SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT
CA2820618C (en) 2010-11-23 2020-04-21 Steven Elmore Use of sulfonylbenzamide compounds in the treatment of systemic lupus erythematosus, lupus nephritis, or sjogren's syndrome
EP2643322B1 (en) 2010-11-23 2017-08-30 Abbvie Inc. Salts and crystalline forms of an apoptosis-inducing agent

Also Published As

Publication number Publication date
CA2903797A1 (en) 2014-10-09
CN107721851B (en) 2021-06-25
JP2018138571A (en) 2018-09-06
IL240779B (en) 2018-04-30
EP4019491A1 (en) 2022-06-29
UY35394A (en) 2014-09-30
MX365343B (en) 2019-05-30
TW201522334A (en) 2015-06-16
CA3183040A1 (en) 2014-10-09
KR102230339B1 (en) 2021-03-23
PE20151809A1 (en) 2015-12-25
UA118667C2 (en) 2019-02-25
EP3954687A1 (en) 2022-02-16
MX2015012000A (en) 2015-12-01
BR122021025062B1 (en) 2022-04-19
CA2903797C (en) 2022-06-21
EP2970263A1 (en) 2016-01-20
LT2970263T (en) 2018-08-27
AU2018203977B2 (en) 2019-07-11
SI2970263T1 (en) 2018-09-28
HK1216644A1 (en) 2016-11-25
EP3569588A1 (en) 2019-11-20
PH12018501094A1 (en) 2019-11-25
PT2970263T (en) 2018-10-03
DK2970263T3 (en) 2018-08-13
CA3090936C (en) 2023-02-07
IL257109B (en) 2019-01-31
UY39847A (en) 2022-09-30
IL240779A0 (en) 2015-10-29
WO2014165044A1 (en) 2014-10-09
NZ711315A (en) 2020-10-30
SG10201701680YA (en) 2017-04-27
CY1120576T1 (en) 2019-07-10
AU2014248742A1 (en) 2015-09-10
HRP20181273T1 (en) 2018-11-16
PH12015501960B1 (en) 2016-01-11
MY192466A (en) 2022-08-22
HUE039046T2 (en) 2018-12-28
CA3090936A1 (en) 2014-10-09
RS57569B1 (en) 2018-10-31
PE20191685A1 (en) 2019-11-19
HK1251231A1 (en) 2019-01-25
JP6578037B2 (en) 2019-09-18
UY39848A (en) 2022-09-30
RU2660424C2 (en) 2018-07-06
BR112015021540A2 (en) 2017-07-18
EP3293185A1 (en) 2018-03-14
TWI735759B (en) 2021-08-11
CN105164128A (en) 2015-12-16
JP2016514137A (en) 2016-05-19
NZ751139A (en) 2020-10-30
AU2014248742B2 (en) 2018-04-05
CN111960944A (en) 2020-11-20
KR20150128994A (en) 2015-11-18
RU2015143637A (en) 2017-04-19
AU2018203977A1 (en) 2018-06-21
CL2015002548A1 (en) 2016-03-18
BR112015021540B1 (en) 2022-04-19
EP2970263B1 (en) 2018-05-09
BR122021025053B1 (en) 2022-09-06
ES2683378T3 (en) 2018-09-26
PL2970263T3 (en) 2018-10-31
CR20150495A (en) 2015-12-03
CN107721851A (en) 2018-02-23
TWI631121B (en) 2018-08-01
JP6357220B2 (en) 2018-07-11
TW201825491A (en) 2018-07-16
CN105164128B (en) 2017-12-12
PH12015501960A1 (en) 2016-01-11

Similar Documents

Publication Publication Date Title
HRP20181273T1 (en) Processes for the preparation of an apoptosis-inducing agent
HRP20181122T1 (en) Process for the preparation of iopamidol
IL245474A0 (en) Process for the preparation of 5-fluoro-1h-pyrazoles
IL281072B (en) Processes for the preparation of pyrimidinylcyclopentane compounds
IL245476A0 (en) Process for the preparation of 5-fluoro-1h-pyrazoles
IL229326A (en) Process for the preparation of n-iodoamides
IL232010A0 (en) Process for the preparation of sulfonamide compounds
IL246188B (en) Process for the preparation of tiacumicin
PL2984100T3 (en) Process for the preparation of drospirenone